

PERSPECTIVES

- 681 **Two Good Choices to Prevent Breast Cancer: Great Taste, Less Filling**
Gabriel N. Hortobagyi and Powel H. Brown
See article p. 696
- 686 **The Lack, Need, and Opportunities for Decision-Making and Informational Tools to Educate Primary-Care Physicians and Women about Breast Cancer Chemoprevention**
Peter M. Ravdin
See article p. 696
- 689 **Long-term Follow-up in Cancer Prevention Trials (It Ain't Over 'Til It's Over)**
Jack Cuzick
See article p. 696
- 692 **Early Changes in Pulmonary Gene Expression following Tobacco Exposure Shed Light on the Role of Estrogen Metabolism in Lung Carcinogenesis**
Jill M. Siegfried
See article p. 707

RESEARCH ARTICLES

- 696 **Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer**
Victor G. Vogel, Joseph P. Costantino, D. Lawrence Wickerham, Walter M. Cronin, Reena S. Cecchini, James N. Atkins, Therese B. Bevers, Louis Fehrenbacher, Eduardo R. Pajon, James L. Wade III, André Robidoux, Richard G. Margolese, Joan James, Carolyn D. Runowicz, Patricia A. Ganz, Steven E. Reis, Wortia McCaskill-Stevens, Leslie G. Ford, V. Craig Jordan, and Norman Wolmark; for the National Surgical Adjuvant Breast and Bowel Project
See perspectives pp. 681, 686 and 689

- 707 **Early Changes in Gene Expression Induced by Tobacco Smoke: Evidence for the Importance of Estrogen within Lung Tissue**
Sibele I. Meireles, Gustavo H. Esteves, Roberto Hirata, Jr., Suraj Peri, Karthik Devarajan, Michael Slifker, Stacy L. Mosier, Jing Peng, Manicka V. Vadhanam, Harrell E. Hurst, E. Jordao Neves, Luiz F. Reis, C. Gary Gairola, Ramesh C. Gupta, and Margie L. Clapper
See perspective p. 692
- 718 **p53-Independent Apoptosis by Benzyl Isothiocyanate in Human Breast Cancer Cells Is Mediated by Suppression of XIAP Expression**
Su-Hyeong Kim and Shivendra V. Singh
- 727 **Berries and Ellagic Acid Prevent Estrogen-Induced Mammary Tumorigenesis by Modulating Enzymes of Estrogen Metabolism**
Harini S. Aiyer and Ramesh C. Gupta
- 738 **Mortality in the Randomized, Controlled Lung Intergroup Trial of Isotretinoin**
J. Jack Lee, Lei Feng, Daniel S. Reshef, Anita L. Sabichi, Brendell Williams, Waree Rinsurongkawong, Ignacio I. Wistuba, Reuben Lotan, and Scott M. Lippman
- 745 **Effects of β -Carotene Supplementation on Molecular Markers of Lung Carcinogenesis in Male Smokers**
Margaret E. Wright, Steve D. Groshong, Kirsti Husgafvel-Pursiainen, Erin Genova, M. Scott Lucia, Henrik Wolff, Jarmo Virtamo, and Demetrius Albanes
- 753 **Resveratrol Suppresses Oxidative Stress and Inflammatory Response in Diethylnitrosamine-Initiated Rat Hepatocarcinogenesis**
Anupam Bishayee, Kendra F. Barnes, Deepak Bhatia, Altaf S. Darvesh, and Richard T. Carroll

764 **Interleukin-6 as a Potential Indicator for Prevention of High-Risk Adenoma Recurrence by Dietary Flavonols in the Polyp Prevention Trial**

Gerd Bobe, Paul S. Albert, Leah B. Sansbury, Elaine Lanza, Arthur Schatzkin, Nancy H. Colburn, and Amanda J. Cross

776 **Identification of Genes Correlated with Early-Stage Bladder Cancer Progression**


Randolph Stone II, Anita L. Sabichi, Jennifer Gill, I-ling Lee, Patrick Adegboyega, Michael S. Dai, Raja Loganantharaj, Marjan Trutschl, Urska Cvek, and John L. Clifford

787 **Combination Effects of Salvianolic Acid B with Low-Dose Celecoxib on Inhibition of Head and Neck Squamous Cell Carcinoma Growth *In vitro* and *In vivo***

Yuan Zhao, Yubin Hao, Hongguang Ji, Yayin Fang, Yinhan Guo, Wei Sha, Yanfei Zhou, Xiaowu Pang, William M. Southerland, Joseph A. Califano, and Xinbin Gu

ABOUT THE COVER

The cover images represent crystallographic structures of estrogen (left), tamoxifen (right), and raloxifene (center) bound to the ligand binding domain of estrogen receptor alpha. Helix 12 (yellow) seals estrogen (left) into the ligand binding domain, allowing full activation of estrogen. The bulky antiestrogenic side chains of tamoxifen and raloxifene prevent helix 12 from sealing and activating the estrogen receptor. The side chain of raloxifene (blue, center panel) shields and neutralizes the critical amino acid D351 (green, center panel), thus allowing few estrogen-like actions to occur in company with the strong antiestrogenic activity of raloxifene. In contrast, the tamoxifen side chain cannot shield and neutralize D351 and thus allows estrogen-like actions to occur. [The cover images appeared originally in Jordan et al., *Cancer Res* 2001;61:6619–23 (left and right panels), and Liu et al., *Cancer Res* 2001;61:3632–39 (center panel), and are reproduced with permission of the American Association for Cancer Research.] These molecular pharmacology studies relate to new, long-term follow-up results of the Study of Tamoxifen and Raloxifene (STAR), which showed strong benefit-to-risk profiles for both raloxifene and tamoxifen in preventing invasive and noninvasive breast cancer. See articles by Vogel et al. (beginning on page 696), Hortobagyi and Brown (beginning on page 681), Ravdin (beginning on page 686), and Cuzick (beginning on page 689) for more information.



Cancer Prevention Research

3 (6)

Cancer Prev Res 2010;3:681-796.

Updated version	Access the most recent version of this article at: http://cancerpreventionresearch.aacrjournals.org/content/3/6
------------------------	---

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org .
Permissions	To request permission to re-use all or part of this article, use this link http://cancerpreventionresearch.aacrjournals.org/content/3/6 . Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.